Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

NCT06395909 ·Status: COMPLETED

Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

NCT05826028 ·Status: COMPLETED

Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients

NCT02623946 ·Status: COMPLETED

LEMTRADA Pregnancy Registry in Multiple Sclerosis

NCT03774914 ·Status: TERMINATED

Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment

NCT05834335 ·Status: COMPLETED

Efficacy and Safety of BG00012 in MS

NCT00168701 ·Status: COMPLETED ·Phase: PHASE2

A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis

NCT06588387 ·Status: COMPLETED

Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study

NCT03369106 ·Status: ACTIVE_NOT_RECRUITING

Spinal Cord Analysis in Multiple Sclerosis

NCT03841903 ·Status: COMPLETED

Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

NCT03793868 ·Status: COMPLETED ·Phase: EARLY_PHASE1

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

NCT00930553 ·Status: COMPLETED ·Phase: PHASE3

Study on Cognitive Disorders of Multiple Sclerosis

NCT01074619 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

NCT05906992 ·Status: RECRUITING ·Phase: PHASE3

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

NCT05893225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

NCT01601119 ·Status: COMPLETED

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

NCT05663853 ·Status: COMPLETED

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

NCT04792567 ·Status: COMPLETED ·Phase: PHASE4

Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study

NCT05197699 ·Status: TERMINATED

Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment

NCT03806387 ·Status: COMPLETED

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

NCT01541618 ·Status: COMPLETED

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

NCT01395316 ·Status: COMPLETED ·Phase: PHASE4

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

NCT01539395 ·Status: WITHDRAWN

Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients

NCT01918501 ·Status: UNKNOWN ·Phase: NA

Study of myMS in Participants With a Diagnosis of Multiple Sclerosis

NCT03111394 ·Status: COMPLETED

Imatinib for Multiple Sclerosis (MS) Relapses

NCT03674099 ·Status: UNKNOWN ·Phase: PHASE2